| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 17,699 | 45,891 | 19,990 | 26,195 |
| Research and development | 5,829 | 7,360 | 8,112 | 10,490 |
| Selling, general and administrative | 17,720 | 18,519 | 18,333 | 18,430 |
| Restructuring expenses | 3,633 | NaN | NaN | NaN |
| Total expenses | 27,182 | 25,879 | 26,445 | 28,920 |
| Gain from operations | -9,483 | 20,012 | -6,455 | -2,725 |
| Net loss on realized contingent milestone and royalty assets | NaN | 37,500* | NaN | 75,137 |
| Trelegy milestone income | NaN | 12,500* | NaN | NaN |
| Interest expense (non-cash) | NaN | 582 | 573 | 663 |
| Interest and other income, net | 3,013 | 3,638 | 4,139 | 1,457 |
| Loss before income taxes | -6,470 | 73,068 | -2,889 | 73,206 |
| Provision for income tax benefit | -1,537 | 12,044 | -6,504 | 18,371 |
| Net loss | -4,933 | 61,024 | 3,615 | 54,835 |
| Net unrealized gain on available-for-sale investments | NaN | NaN | 42 | -10 |
| Total comprehensive income (loss) | NaN | NaN | 3,657 | 54,825 |
| Basic EPS | -0.1 | 1.199 | 0.07 | 1.09 |
| Diluted EPS | -0.1 | 1.136 | 0.07 | 1.08 |
| Basic Average Shares | 51,279,000 | 50,865,000 | 50,520,000 | 50,177,000 |
| Diluted Average Shares | 51,279,000 | 53,688,000 | 51,908,000 | 50,726,000 |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)